MYELOPROLIFERATIVE NEOPLASMS TREATMENT MARKET ANALYSIS

Myeloproliferative Neoplasms Treatment Market, By Disease Type (Essential Thrombocythemia (ET), Myelofibrosis (MF), Polycythemia Vera (PV)), By Drug Class (Tyrosine Kinase Inhibitors, Janus kinase inhibitors (JAKi), Antimetabolites, Others (alkylating agents, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Myeloproliferative Neoplasms Treatment Market: Key Developments

On June 10, 2022, AbbVie, a pharmaceutical company headquartered in Illinois, U.S., announced new data from its phase 2 study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF). These preliminary findings show spleen volume and symptomatic improvement in this cohort.
On May 26, 2022, Protagonist Therapeutics, a clinical stage biopharmaceutical company, announced new data from its ongoing phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera (PV). It was presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from June 3, 2022.

Myeloproliferative Neoplasms Treatment Market Report Snapshots